IMRX — Immuneering Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1790340 ·
Last close
$4.16
Market Cap
$269.14M
52W High
$8.48
52W Low
$3.86
ADV30
654,163
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,999,964 | -17,270,427 | 202,055,327 | 41,324,682 | 11,320,301 |
| Mar 2026 | 0 | — | -15,334,539 | -13,460,895 | 214,809,790 | 47,321,566 | 8,291,619 |
| Dec 2025 | 0 | — | -13,751,943 | -11,580,010 | 231,985,010 | 128,645,025 | 13,501,042 |
| Sep 2025 | 0 | — | -15,380,300 | -14,964,875 | 241,056,266 | 227,563,077 | 13,079,834 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,752,670
Investing CF
$-141,318,060
Financing CF
$213,039,914
CapEx
$-238,462
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,051,406
Inventory
—
Receivables
—
ST Investments
$108,575,637
EBIT TTM
$-63,466,746
Pretax Income TTM
$-57,274,086
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,375,728 | -56,024,898 | 231,985,010 | 13,501,042 | 218,483,968 | -45,344,595 |
| Dec 2024 | 0 | -64,071,655 | -61,036,608 | 52,714,413 | 11,328,187 | 41,386,226 | -54,999,571 |
| Dec 2023 | 0 | -58,413,285 | -53,471,622 | 102,584,538 | 12,008,355 | 90,576,183 | -48,968,634 |
| Dec 2022 | 316,952 | -51,745,339 | -50,513,568 | 122,367,283 | 12,517,028 | 109,850,255 | -44,101,265 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,190,019
NetIncome TTM
$-54,676,576
OpCashFlow TTM
$0
Assets (Latest)
$231,985,010
Forward EPS
$-1.26
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $4.16 · call volume: 27 · put volume: 419
Expected Move to 2026-11-20:
±$1.20
(28.85%) —
implied range
$2.96 –
$5.36
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $269.28M | $0.25 | — |
| IFRX | InflaRx N.V. | $268.21M | $1.82 | — |
| GLSI | Greenwich LifeSciences, Inc. | $272.87M | $18.59 | — |
| QTTB | Q32 Bio Inc. | $274.77M | $9.23 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $263.52M | $0.15 | — |
News headlines (Yahoo Finance, 1h cache)
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
2026-09-28 11:30 · Yahoo
Immuneering to Present at the ESMO Congress 2026
2026-09-24 11:30 · Yahoo
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
2026-09-10 11:30 · Yahoo
Immuneering to Participate in Upcoming Investor Conferences
2026-09-03 20:05 · Yahoo
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
2026-08-26 21:16 · Yahoo
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 11:30 · Yahoo
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
2026-07-21 20:05 · Yahoo
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
2026-07-15 16:00 · Yahoo
Immuneering Appoints Andrew Gengos as Chief Financial Officer
2026-06-15 11:30 · Yahoo
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
2026-06-01 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.